Clinicopathologic reports, case reports, and small case series: 0.01% becaplermin gel for the treatment of a chronic orbital ulcer after exenteration.
Yassur
I
I
Department of Ophthalmology, Krieger Eye Institute, Sinai Hospital of Baltimore, 2411 W Belvedere Ave, Baltimore, MD 21215, USA.
Hirschbein
M J
MJ
Karesh
J W
JW
D000925:Anticoagulants / Q000627:therapeutic use*; D000077214:Becaplermin; D002908:Chronic Disease; D004847:Epithelial Cells / Q000187:drug effects / Q000473:pathology; D005782:Gels; D006801:Humans; D008297:Male; D008545:Melanoma / Q000601:surgery; D008875:Middle Aged; D017233:Orbit Evisceration / Q000009:adverse effects*; D009916:Orbital Diseases / Q000188:drug therapy* / Q000209:etiology; D009918:Orbital Neoplasms / Q000601:surgery; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use*; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins / Q000627:therapeutic use; D014456:Ulcer / Q000188:drug therapy* / Q000209:etiology
D000925:Anticoagulants; D005782:Gels; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D000077214:Becaplermin